These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 25995284)

  • 1. Undetectable pregnancy-associated plasma protein-A in antenatal serum Down's syndrome screening: a case of assay interference.
    Williams C; Hambridge K; Petchey M; Martin JA; Spencer K
    Ann Clin Biochem; 2015 Sep; 52(Pt 5):615-9. PubMed ID: 25995284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interference in the autoDELFIA(R) hAFP immunoassay and effect on second-trimester Down's syndrome screening.
    Mannings L; Trow S; Newman J; Nix B; Evans C
    Ann Clin Biochem; 2011 Sep; 48(Pt 5):438-40. PubMed ID: 21795408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
    Spencer K
    Ann Clin Biochem; 2005 Jan; 42(Pt 1):30-40. PubMed ID: 15802030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoassay-Amplified Responses Using a Functionalized MoS
    Chiu NF; Tai MJ; Nurrohman DT; Lin TL; Wang YH; Chen CY
    Int J Nanomedicine; 2021; 16():2715-2733. PubMed ID: 33859474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
    Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
    Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Screening by maternal serum markers for Down's syndrome].
    Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-trimester or second-trimester screening, or both, for Down's syndrome.
    Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
    N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
    Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated measures screening for Down's Syndrome.
    Wright DE; Bradbury I
    BJOG; 2005 Jan; 112(1):80-3. PubMed ID: 15663402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
    N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down's syndrome: current screening techniques.
    White RS
    South Med J; 1989 Dec; 82(12):1483-6. PubMed ID: 2480649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antenatal screening for Down's syndrome with the quadruple test.
    Wald NJ; Huttly WJ; Hackshaw AK
    Lancet; 2003 Mar; 361(9360):835-6. PubMed ID: 12642052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of the pregnancy-associated plasma protein-A assay on the Beckman Coulter Access(®) platform: suitability for use in first trimester Down's syndrome screening.
    Lambert-Messerlian G; Palomaki GE; Canick JA
    J Med Screen; 2010; 17(3):109-13. PubMed ID: 20956719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple-marker screening for Down's syndrome: a method of assessing the statistical robustness of proposed tests.
    Morris JK; Bestwick J; Wald NJ
    J Med Screen; 2008; 15(2):55-61. PubMed ID: 18573771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Focus on preanalytics for Down's syndrome screening during first trimester of pregnancy].
    Gebeile R; Roger C; Doche C; Doche L
    Ann Biol Clin (Paris); 2014; 72(2):207-12. PubMed ID: 24736141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-resolved immunofluorometric assay of pregnancy-associated plasma protein A in maternal serum screening for Down's syndrome in first trimester of pregnancy.
    Qin QP; Nguyen TH; Christiansen M; Larsen SO; Nørgaard-Pedersen B
    Clin Chim Acta; 1996 Oct; 254(2):113-29. PubMed ID: 8896900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More invasive procedures are done to detect each case of Down's syndrome in younger women.
    Marttala J; Ranta JK; Kaijomaa M; Nieminen P; Laitinen P; Kokkonen H; Romppanen J; Hamalainen E; Kultti J; Tekay A; Ulander VM; Honkasalo T; Ryynanen M
    Acta Obstet Gynecol Scand; 2011 Jun; 90(6):642-7. PubMed ID: 21355862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal biochemical screening for Down's syndrome and neural tube defects.
    Wald NJ; Kennard A
    Curr Opin Obstet Gynecol; 1992 Apr; 4(2):302-7. PubMed ID: 1373963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will PAPP-A be a biochemical marker for screening of Down's syndrome in the first trimester?
    el Farra K; Grudzinskas JG
    Early Pregnancy; 1995 Mar; 1(1):4-12. PubMed ID: 9363230
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prenatal screening: the example of Down's syndrome screening].
    Donner C; Daelemans C; Ceysens G
    Rev Med Brux; 2015 Sep; 36(4):207-11. PubMed ID: 26591302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.